News

Harry P. Erba, MD, PhD, recently shared treatment considerations he would make when treating patients with polycythemia vera (PV) based on 3 case scenarios.

A recent warning issued by the FDA advised that breast implants may increase an individual’s risk of developing anaplastic large cell lymphoma.

Daniel A. Barocas, MD, discusses a study that compared differences in quality of life among patients who have undergone radical prostatectomy, external beam radiotherapy, brachytherapy or active surveillance for low-risk prostate cancer.

Evan Y. Yu, MD, discusses the current treatment options for metastatic urothelial carcinoma, the unmet needs that still exist in this space, and the possibilities for the future treatment landscape.

The PD-L1 inhibitor durvalumab demonstrated compelling clinical activity and a manageable safety profile as second-line therapy for locally advanced or metastatic urothelial cancer.

A new drug application (NDA) for olaparib (Lynparza) as a maintenance therapy in relapsed patients with platinum-sensitive ovarian cancer has been granted a priority review by the FDA.

Adam M. Brufsky, MD, PhD, discusses considerations for using the bone-targeted agents denosumab and zoledronic acid in patients with breast cancer.

The PARP inhibitor niraparib (Zejula) has been approved by the FDA for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy.

Steven J. Skates, PhD, discusses a study on early detection of ovarian cancer using the Risk of Ovarian Cancer Algorithm (ROCA), in which CA125 was tested in women with high risk who chose to postpone surgery.

Andre Goy, MD, highlights what researchers can expect next in the field of MCL in both the frontline and relapsed/refractory settings given the recent pivotal data from clinical trials.

Leslie Schover, PhD, discusses ways in which providers can better address sexuality issues associated with treatment for patients with breast cancer.

Stephan Grupp, MD, PhD, discusses results of the phase II ELIANA study and the next steps with CAR T-cell therapy in ALL.

Pembrolizumab has been recommended for approval by the EMA’s Committee for Medicinal Products for Human Use for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma.

Michel Sadelain, MD, PhD, discusses CRISPR and its effect on CAR T cells.

Tanguy Seiwert, MD, discusses advances and next steps with immunotherapy, as well as the overall challenges and goals for treating patients with head and neck cancer.

Nivolumab (Opdivo) has been recommended for approval by EMA’s Committee for Medicinal Products for Human Use for the treatment of patients with squamous cell cancer of the head and neck following progression on platinum-based therapy.

The first-in-class IDO1 inhibitor epacadostat (INCB024360), currently being investigated in combination with the PD-1 inhibitor pembrolizumab (Keytruda), could be an exciting new FDA approval for patients with stage III/IV unresectable or metastatic melanoma.

The antibody-drug conjugate sacituzumab govitecan demonstrated an overall response rate of 31% in heavily pretreated patients with metastatic urothelial cancer.

Susan F. Slovin, MD, PhD, offers her expert insight on the current state of immunotherapy in prostate cancer.

Sara Hurvitz, MD, discusses ongoing advances that continue to revolutionize the treatment of patients with HER2+ breast cancer.

Emma L. Barber, MD, discusses her research into neoadjuvant chemotherapy for ovarian cancer and its effect on hospital readmission rates.

The PD-L1-inhibitor avelumab (Bavencio) has been granted an accelerated approval by the FDA for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma.

James B. Yu, MD, discusses the current data in support of using moderate hypofractionation in prostate cancer, as well as recent data showing how genomic testing can help with treatment decision making postoperatively.

Brian Hemphill, MD, provides insight on some of the challenges currently being faced in GI malignancies—specifically, colorectal cancer, pancreatic cancer, and gastic cancer—and how molecular profiles of tumors will dramatically change outcomes for these patients.

Arjun Balar, MD, discusses the treatment considerations he makes when treating patients with urothelial carcinoma, the role of PD-L1 tumor expression and immune checkpoint inhibitors, and the potential for new immunotherapy agents in this space.

The combination of rituximab, bendamustine, and low-dose cytarabine demonstrated a high complete response rate as an induction regimen for elderly patients with mantle cell lymphoma.

Giuseppe Curigliano, MD, PhD, discusses recent trials of immunotherapy and chemotherapy in triple-negative breast cancer, as well as the future role of immunotherapy in the treatment of breast cancer.

Researchers in the Netherlands have found that using a gradual or “stepped” approach to providing psychosocial support for patients diagnosed with head and neck or lung cancers not only improves their quality of life but is also cost-effective.

Progression-free survival was improved by adding abemaciclib to fulvestrant compared with fulvestrant alone in women with HR+/HER2-negative breast cancer enrolled in the phase III MONARCH 2 study.

A new drug application for the MEK inhibitor binimetinib as a treatment for patients with <em>NRAS</em>-mutant advanced melanoma has been withdrawn by Array BioPharma.